Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LARGE xylosyl- and glucuronyltransferase 2 (LARGE2) is a bifunctional enzyme with alpha-1,3-xylosyltransferase and beta-1,3-glucuronyltransferase activities involved in the maturation and functional modification of alpha-dystroglycan and certain proteoglycans by glycosylation. It catalyzes the sequential addition of repeating disaccharide units (xylose and glucuronic acid) to form heteropolysaccharide chains, essential for extracellular matrix protein binding, particularly laminin. This modification is crucial for proper basement membrane stability and protein interactions. LARGE2 is mainly localized to the Golgi apparatus and exhibits a tissue distribution distinct from its paralog LARGE1, with high expression in kidney and placenta. Mutations or functional defects in LARGE2 are implicated in certain forms of muscular dystrophy associated with abnormal glycosylation of dystroglycan. Unlike LARGE1, LARGE2 can also modify specific proteoglycans beyond alpha-dystroglycan, suggesting a broader substrate specificity and specialized cellular roles in extracellular matrix organization and stability[1][2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on LARGE xylosyl- and glucuronyltransferase 2 (LARGE2).